Alkem announces the launch of semaglutide injections for diabetes and weight management in India, priced at approximately $25 per month. The company has also revised its fair value to ₹5,911.29 and declared an interim dividend of ₹43 per share for FY26. Additionally, GMP certificates have been obtained for their facilities in Daman and Baddi.

Alkem Labs has increased its investment in a new formulations plant in Ujjain to ₹1036 crore, almost doubling the original ₹533 crore allocation. The expansion of the facility will be carried out in phases.

Alkem Laboratories increases its investment for a new Ujjain plant in Madhya Pradesh from ₹533 crore to ₹1,036 crore, signaling an expansion of operations and commitment to the region's pharmaceutical industry. The investment will be phased over time.

Alkem Labs increases investment in their Ujjain unit to 1,036 crores INR for the expansion of a greenfield facility, marking a doubling of initial funds from 533 crores.

Indian pharmaceutical company Alkem Laboratories has established a new wholly-owned subsidiary named Alkem Pharmaceuticals Scientific Office FZ LLC in Dubai Healthcare City, UAE, for manufacturing products and securing registrations with an initial investment of AED 3.7M.